



F16.2

Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...






Docket No. M1015/7071 Screening for Tumorigenesis Inhibition...


Average % Cell Growth From 0-48 Hours

-4-- Series1 ·784 ന Q 300 250. 200 50 150 100 % Growth

Docket No. M1015/7071
Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...




Fi6.6




F16.7

Docket No. M1015/7071




F16.9


Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



01.017




F16.11



F16.12


Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



Diagnostic Tumor Markers, Drug Screening for Tumorigenesis

Docket No. M1015/7071

F16 15




Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...

71916

**Binding Assay** 

Docket No. M1015/7071

Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...




-Series1 J7 8 = 7 time ·786=7 F16.18 0 80 09 70 50 40 30 20 10 % Growth ...noitididal Screening for Tumorigenesis

Diagnostic Tumor Markers, Drug

Docket No. M1015/7071

Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



PSMGFR (alloid + Lyself (+fms+)

Lyself (+fms+)

PSMGFR (alloid + Lyself (+fms+)

PSMGFR (alloid +

F16.20